We advised the joint book-running managers on the SEC-registered equity offering

Davis Polk advised the joint book-running managers in connection with a $143.7 million SEC-registered follow-on offering of 4,356,060 shares of common stock by RAPT Therapeutics, Inc., which included 568,181 shares from the full exercise of the underwriters’ option to purchase additional shares. The common stock is listed on the Nasdaq Global Market under the symbol “RAPT.”

RAPT Therapeutics is a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases.

The Davis Polk corporate team included partner Emily Roberts and associates Jonathan Bye and Paula Gergen. The intellectual property and technology transactions team included partner David R. Bauer and associates Mikaela Dealissia and Shuang Ci. Counsel Marcie A. Goldstein provided FINRA advice. Members of the Davis Polk team are based in the Northern California and New York offices.